The Efficacy and Safety of Xinjia Xuanbai Chengqi Granules in Acute Exacerbation of COPD: A Multicentre, Randomised, Double-Blind, Controlled Trial
Table 2
Demographic characteristics and baseline data of the participants.
Item
Group A (n = 106)
Group B (n = 107)
Group C (n = 110)
Statistics
value
Gender
Male
75
86
92
5.86
0.053
Female
31
21
18
Age (years)
67.17 ± 8.06
68.45 ± 7.28
68.28 ± 8.42
0.82
0.442
Vital signs
Temperature (°C)
36.52 ± 0.51
36.46 ± 0.37
36.44 ± 0.43
0.91
0.402
Heart rate (times/min)
85.32 ± 13.20
82.70 ± 11.73
84.79 ± 11.34
1.40
0.248
Respiratory rate (times/min)
20.36 ± 1.74
20.31 ± 1.80
20.17 ± 2.18
0.27
0.762
SBP (mmHg)
134.34 ± 17.40
132.09 ± 18.46
133.01 ± 17.32
0.43
0.650
DBP (mmHg)
80.12 ± 9.44
78.51 ± 10.34
78.82 ± 10.97
0.73
0.481
Past history (%)
91 (85.85)
94 (87.85)
97 (88.18)
0.32
0.853
Allergic history (%)
21 (19.81)
26 (24.30)
27 (24.55)
0.89
0.640
AE times within last year
1.18 ± 1.01
1.17 ± 1.33
1.08 ± 1.17
0.22
0.804
Hospitalisation times for AE
0.80 ± 0.83
0.81 ± 0.80
0.78 ± 1.04
0.04
0.962
FEV1% (numbers)
52.35 ± 14.84 (62)
51.19 ± 14.75 (63)
52.32 ± 13.27 (67)
0.14
0.872
Efficacy outcomes
Phlegm score
38.08 ± 25.19
41.30 ± 29.78
38.53 ± 50.05
0.24
0.786
Wexner score
7.17 ± 3.56
7.55 ± 3.71
7.05 ± 3.64
0.55
0.577
mMRC
2.35 ± 0.81
2.38 ± 0.75
2.25 ± 0.84
0.76
0.470
pH
7.41 ± 0.03
7.40 ± 0.04
7.40 ± 0.04
0.61
0.545
PaO2 (mmHg)
75.49 ± 20.79
76.30 ± 21.07
77.19 ± 30.49
0.12
0.886
PaCO2 (mmHg)
41.55 ± 9.44
42.73 ± 9.92
42.54 ± 14.35
0.30
0.741
TCM syndrome score
5.58 ± 2.21
5.47 ± 2.25
5.29 ± 2.15
0.46
0.631
Note. SBP: systolic blood pressure; DBP: diastolic blood pressure; AE: acute exacerbation; TCM: traditional Chinese medicine; mMRC: modified British medical research council.
